Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Dyax (NASDAQ:DYAX) lost 34% of their value today, falling off a cliff after first-quarter earnings came out.
So what: First-quarter net sales increased slightly from a year ago, to $12.0 million, but analysts expected $16.0 million in revenue, so this is a huge miss. It's no wonder that net loss of $11.2 million equates to $0.11 per share, more than double the $0.05 per share loss analysts expected.
Now what: The company is having trouble with its KALBITOR business, experiencing fewer new patients, and fewer treatments in the quarter. I'm not a fan of speculating on a company like this, especially when its flagship product isn't being well received by the market. I'd jump ship and wait until strong results come out to reevaluate the company, because there's no significant profit on the horizon.
Interested in more info on Dyax? Add it to your watchlist by clicking here.
Fool contributor Travis Hoium has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
What's Juno Therapeutics Worth to Celgene?
Celgene may be considering a multibillion-dollar bid to acquire Juno.
Why Ascena Retail Group Inc. Stock Plunged 62% in 2017
The parent company of maurices just finished a tough year. Here's what investors need to know.
3 Easy Ways to Invest in India for 2018
Here's how to get access to this exciting emerging market.